Perioperative Management of Diabetes Mellitus Author: Nadia A. Khan, MD; William A. Ghali, MD; Susan E. Spratt, MD; Melanie E. Mabrey, MSN, ACNP, BC-ADM
Editorial changes - 2012-01-03
Author information and module status
Elements of Risk
Whom and How to Assess
Interventions to Decrease Risk
Patient Education
Follow-up
Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Frequently Asked Questions
Elements of Risk
What is the cardiac risk associated with diabetes mellitus?
What is the risk of developing wound infections if one has diabetes mellitus?
What is the risk of developing hypoglycemia?
Whom and How to Assess
How should cardiac risk be assessed among patients with diabetes?
How should risk for hypoglycemia be assessed?
How should risk for DKA be assessed?
How is the surgery type related to glucose control?
How is the anesthesia type related to glucose control?
Should we test for baseline glycemic control?
What routine tests are relevant for patients with diabetes?
What additional cardiac tests are important and when should they be performed for further risk stratification?
Interventions to Decrease Risk
What are the non-drug interventions to reduce complications?
How do we manage diabetic medications before surgery?
How do we manage diabetic medications for patients with potential infection?
How do we manage diabetic medications during surgery?
How do we manage diabetic medications after surgery?
What is the range of glucose levels that I should aim for after surgery?
Patient Education
What should I tell my patient about diet?
What should I tell my patient about diabetic medications before surgery?
Follow-up
How should I follow-up patients for diabetes-related complications?
How often should I perform laboratory tests?
How often should glucose levels be monitored postoperatively?
| Patient Information
Melanie E. Mabrey, MSN, ACNP, BC-ADM, is a consultant and speaker for Sanofi-Aventis Pharmaceuticals. Nadia A. Khan, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Susan E. Spratt, MD, is a consultant and speaker for Sanofi Aventis and Novo Nordisk. William A. Ghali, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Deborah Korenstein, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Richard B. Lynn, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.

The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted © 2012 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.